# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 11-20 of 563 results.
A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP
Status: Recruiting
Last Changed: Mar 13, 2020
First Received: Apr 18, 2016
Disease(s): B-cell Lymphoma
Intervention(s): selinexor, Rituximab, Dexamethasone, Oxaliplatin, Cisplatin, Cytarabine, Gemcitabine
Locations: Institut Jules Bordet, Bruxelles, Belgium
CHU Dijon, Dijon, France
CHRU de Lille - Hôpital Claude Huriez, Lille, France
CHU Montpellier - Hôpital Saint Eloi, Montpellier, France
CHU Nancy - Hôpital de Brabois, Nancy, France
... and 4 other locations.
R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma
Status: Recruiting
Last Changed: Jun 04, 2020
First Received: Jan 02, 2020
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Rituximab, Lenalidomide, Cyclophosphamide, Epirubicin, Vincristine, Prednisone, Methotrexate
Locations: Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma
Status: Recruiting
Last Changed: Jan 31, 2020
First Received: Jan 31, 2020
Disease(s): Large B-cell Lymphoma
Intervention(s): BZ019
Locations: Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin, China
Tianjin medical university cancer institute and hospital, Tianjin, China
Quikin CD19-CART in Patients With r/r B-cell Lymphoma
Status: Recruiting
Last Changed: Mar 16, 2020
First Received: Dec 30, 2019
Disease(s): B-cell Lymphoma
Intervention(s): CD19-Specific Chimeric Antigen Receptor T cells with PD1 knockout
Locations: the First Affliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China
Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)
Status: Not yet recruiting
Last Changed: Apr 21, 2020
First Received: Mar 09, 2020
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): molecular characterization
Locations: Irst Irccs, Meldola, FC, Italy
Ospedale S. Maria delle Croci RAVENNA, Ravenna, RA, Italy
Ospedale Infermi, Rimini, Italy
Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Status: Not yet recruiting
Last Changed: Jan 31, 2019
First Received: Jan 31, 2019
Disease(s): Refractory B-Cell Lymphoma
Intervention(s): Anti-CD19 iCAR NK Cells
Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Status: Not yet recruiting
Last Changed: Jan 31, 2019
First Received: Jan 31, 2019
Disease(s): Refractory B-Cell Lymphoma
Intervention(s): Anti-CD19/CD22 CAR NK Cells
A Study of MIL62 Combined With ICP-022 for the Treatment of R/R CD20+B Cell Lymphoma
Status: Not yet recruiting
Last Changed: Jun 17, 2020
First Received: Mar 11, 2020
Disease(s): B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory
Intervention(s): ICP-022, Recombinant humanized monoclonal antibody MIL62 injection
Locations: Beijing Hospital, Beijing, Beijing, China
Beijing Shijitan hospital, capital medical university, Beijing, Beijing, China
Cancer hospital, Chinese academy of medical sciences, Beijing, Beijing, China
Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Status: Not yet recruiting
Last Changed: Jan 30, 2019
First Received: Oct 02, 2018
Disease(s): Refractory B-Cell Lymphoma
Intervention(s): Anti-CD22 CAR NK Cells
Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Status: Not yet recruiting
Last Changed: Jan 31, 2019
First Received: Oct 01, 2018
Disease(s): Refractory B-Cell Lymphoma
Intervention(s): Anti-CD19 CAR NK Cells